Who We Are
Spherix Global Insights is an independent business intelligence and market research agency, specializing in renal, autoimmune, neurologic and rare disease markets. Our aim is to apply our commercial experience and unique relationships within core specialty markets to translate data into insight, enabling our clients to make smarter business decisions.
We aspire to be the intelligence provider of choice in the select therapy areas we cover and therefore we invest in our client relationships as long-term partnerships. Our intelligence teams have extensive experience in market research, data analysis, pharma brand management, and strategic marketing. We understand the business context of the research because our leadership has been in the decision-maker’s seat before and understands the challenges and missed opportunities caused by data you can’t be truly confident in.
Invest In Intelligence That Delivers.
How We Do It
Our research is conducted in collaboration with our proprietary networks of engaged physicians, ancillary healthcare professionals and patients. By cultivating our own proprietary networks, we can control the quality of the respondents and ensure that you are getting insights from a group representative of your customer base.
Asking the real questions you cannot address with other research models
Developing our own physician and patient networks
Analyzing findings and strategizing about the commercial implications
Delivering actionable, high value reports specific to the key issues in our target markets
We provide disease-specific research reports in the form of our rapid turnaround monitor RealTime Dynamix™, our patient chart analysis RealWorld Dynamix™, or our assessment of evolving treatment paradigms Market Dynamix™, as well as consulting and custom analysis.
At Spherix, the report is only part of the deliverable. Our insights are customized to your business needs and we thrive on delivering not just data, but context. Our experts provide input and interpretation of the findings to finely tune the final reports.